Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

51.21 +0.56 (+1.11%)
Official Closing Price Updated: 4:10 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,130,634
Open 50.79
Bid (Size) 51.21 (100)
Ask (Size) 51.50 (200)
Prev. Close 50.65
Today's Range 50.33 - 51.61
52wk Range 42.52 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 4.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Pharmaceutical Stocks to Buy at a Discount ↗
Investors are currently so focused on one type of drug that even good companies are being left on the sidelines. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-9.8%
-9.8%
1 Month
+8.4%
+8.4%
3 Month
+8.4%
+8.4%
6 Month
+2.5%
+2.5%
1 Year
-12.8%
-12.8%

More News

Read More
News headline image
1 Large-Cap Stock on Our Buy List and 2 We Turn Down
Via StockStory
News headline image
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Via StockStory
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ ↗
Via Stocktwits
News headline image
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
Amazon Unleashes AI Frontier Agents: A New Era of Autonomous Digital Workers
Via TokenRing AI
Topics Artificial Intelligence Economy
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend? ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Bristol-Myers (BMY) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a Compelling Mix of High Yield and Financial Strength for Dividend Investors ↗
Via Chartmill
News headline image
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 51.21
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 12/10/25 04:10 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 113.79B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 114B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.